Buprenorphine, buprenorphine with naloxone, methadone
Brand: Subutex®, Suboxone film, Aspen Methadone Syrup, Biodone Forte
PBAC's latest decision on Buprenorphine, buprenorphine with naloxone, methadone: Recommended (2023). Considered for Treatment of opioid dependence within a framework of medical, social and psychological treatment. Maintenance and detoxification (withdrawal).
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Adults and patients with opioid dependence requiring treatment through community pharmacy dosing or correctional facilities, receiving buprenorphine (sublingual tablets and modified-release injections), buprenorphine with naloxone (sublingual films), or methadone (oral liquid).
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
Other
Economic model
BIA only
ICER note
This is a post-market review of existing PBS listings addressing affordability and access issues. No economic evaluation or ICER was conducted; the submission is a policy/listing restructuring exercise.